Opinion|Videos|March 13, 2025
How BTK Inhibitors Might Address Unmet Treatment Needs in CSU
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors appear to offer faster symptom relief and higher complete response rates compared with current chronic spontaneous urticaria (CSU) treatments like antihistamines and omalizumab while potentially requiring less frequent dosing and showing favorable safety profiles.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do data from these trials compare to results you see in practice with other, non-BTK options for CSU management?
Advertisement
Related to this article
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5